Combined treatment with dendritic cells and 5-fluorouracil elicits augmented nk cell-mediated antitumor activity through the tumor necrosis factor-α pathway

Journal of Immunotherapy

Volumn 33, Issue 5, 2010, Pages 467-474

  Nagasaki, Eijiro ^a,b   Takahara, Akitaka ^b,c   Koido, Shigeo ^c,d   Sagawa, Yukiko ^a   Aiba, Keisuke ^b   Tajiri, Hisao ^c   Yagita, Hideo ^e   Homma, Sadamu ^a  

^a Institute of DNA Medicine   (Japan)

^b Hematology and Oncology   (Japan)

^c Division of Gastroenterology and Hepatology   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Caspase 8; Dendritic cell; Natural killer cell; Tumor necrosis factor a

Indexed keywords

CASPASE 8; CD4 ANTIGEN; CD8 ANTIGEN; CISPLATIN; CONCANAMYCIN A; DENDRITIC CELL VACCINE; FLUOROURACIL; IRINOTECAN; LIPOPOLYSACCHARIDE; MITOMYCIN C; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D; PROCASPASE 8; RETINOIC ACID INDUCIBLE PROTEIN I; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; BLOCKING ANTIBODY; CANCER VACCINE; CELL EXTRACT; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LYSATE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPENIA; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; INHIBITION KINETICS; INOCULATION; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; UPREGULATION; ANIMAL; ANTIGEN PRESENTATION; C57BL MOUSE; CANCER TRANSPLANTATION; COLORECTAL NEOPLASMS; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; SPLEEN; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BLOCKING; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL EXTRACTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; FLUOROURACIL; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; SPLEEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953041129     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181d36726     Document Type: Article

References (43)

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;91:271-296.
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
3. Shurin MR. Dendritic cells presenting tumor antigen. Cancer Immunol Immunother. 1996;43:158-164.
4. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol. 2000;184:245-273.
5. Malmberg K, Bryceson Y, Carlsten M, et al. NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunol Immunother. 2008;57: 1541-1552.
6. Rosenberg S, Yang J, Restifo N. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
7. Zhang T, Herlyn D. Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother. 2009;58:475-492.
8. Yang S, Haluska F. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme-and fas-mediated pathways. J Immunol. 2004;172:4599-4608.
9. Bergmann-Leitner E, Abrams S. Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol Immunother. 2001;50:445-455.
10. Lichtenstein A, Pende D. Enhancement of natural killer cytotoxicity by cis-diamminedichloroplatinum (II) in vivo and in vitro. Cancer Res. 1986;46:639-644.
11. Lundqvist A, Abrams S, Schrump D, et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 2006;66:7317-7325.
12. Hallett W, Ames E, Motarjemi M, et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol. 2008;180:163-170.
13. Milner A, Palmer D, Hodgkin E, et al. Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cells. Cell Death Differ. 2002;9:287-300.
14. Ehrhardt H, Hacker S, Wittmann S, et al. Cytotoxic druginduced, p53-mediated upregulation of caspase-8 in tumor cells. Oncogene. 2008;27:783-793.
15. Thirion P, Michiels S, Pignon J, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol. 2004;22:3766-3775.
16. Wolpin B, Mayer R. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134:1296-1310.
17. Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20:3617-3627.
18. Douillard J, Hoff P, Skillings J, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20:3605-3616.
19. Kayagaki N, Yamaguchi N, Nagao F, et al. Polymorphism of murine fas ligand that affects the biological activity. Proc Natl Acad Sci U S A. 1997;94:3914-3919.
20. Kayagaki N, Yamaguchi N, Nakayama M, et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol. 1999;163:1906-1913.
21. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1993;176:1693-1702.
22. Inaba K, Inaba M, Deguchi M, et al. Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow. Proc Natl Acad Sci U S A. 1993;90:3038-3042.
23. Homma S, Toda G, Gong J, et al. Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J Gastroenterol. 2001;36:764-771.
24. Liu L, Chahroudi A, Silvestri G, et al. Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med. 2002;8:185-189.
25. Jerome K, Sloan D, Aubert M. Measuring T-cell-mediated cytotoxicity using antibody to activated caspase 3. Nat Med. 2003;9:4-5.
26. Ljunggren H, Karre K. In search of the "missing self": MHC molecules and NK cell recognition. Immunol Today. 1990; 11:237-244.
27. Cerwenka A, Lanier L. Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev. 2001;181:158-169.
28. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;475:187-376.
29. Fernandez N, Lozier A, Flament C, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med. 1999;5: 405-411.
30. Degli-Esposti M, Smyth M. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol. 2005;5:112-124.
31. Fernandez N, Flament C, Crepineau F, et al. Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk. Eur Cytokine Netw. 2002;13:17-27.
32. Borg C, Jalil A, Laderach D, et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood. 2004;104: 3267-3275.
33. Andrews D, Scalzo A, Yokoyama W, et al. Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol. 2003;4:175-181.
34. Ferlazzo G, Pack M, Thomas D, et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci USA. 2004;101:16606-16611.
35. Lucas M, Schachterle W, Oberle K, et al. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity. 2007;26:503-517.
36. Granucci F, Zanoni I, Pavelka N, et al. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J Exp Med. 2004;200:287-295.
37. Andoniou C, Van Dommelen S, Voigt V, et al. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat Immunol. 2005;6:1011-1019.
38. Munz C, Dao T, Ferlazzo G, et al. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood. 2005;105:266-273.
39. Jinushi M, Takehara T, Kanto T, et al. Critical role of MHC class I-related chain A and B expression on IFN-alphastimulated dendritic cells in NK cell activation: Impairment in chronic hepatitis C virus infection. J Immunol. 2003;170: 1249-1256. (Pubitemid 36139490)
40. Kijima M, Yamaguchi T, Ishifune C, et al. Dendritic cellmediated NK cell activation is controlled by Jagged2-notch interaction. Proc Natl Acad Sci U S A. 2008;105:7010-7015.
41. Gerosa F, Baldani-Guerra B, Nisii C, et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med. 2002;195:327-333.
42. Piccioli D, Sbrana S, Melandri E, et al. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med. 2002;195:335-341.
43. Gasser S, Orsulic S, Brown E, et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436:1186-1190.